Updated recommendation from the Advisory Committee on Immunization Practices for revaccination of persons at prolonged increased risk for meningococcal disease
from Morbidity and Mortality Weekly Report
The Advisory Committee on Immunization Practices recommends quadrivalent meningococcal conjugate vaccine, for all persons aged 11—18 years and for persons aged 2—55 years at increased risk for meningococcal disease. MCV4 is licensed as a single dose. Because of the high risk for meningococcal disease among certain groups and limited data on duration of protection, at its June 2009 meeting ACIP recommended that persons previously vaccinated with either MCV4 or MPSV4, who are at prolonged increased risk for meningococcal disease should be revaccinated with MCV4.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063